In December 2024, the FDA approved Zepbound (tirzepatide) as the first prescription medication for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, a use case distinct from its original obesity and weight-management indication. The approval marked a notable expansion for a GLP-1/GIP medication into a condition not directly related to blood sugar or, on its face, breathing.
Why a Weight-Loss Drug Treats Sleep Apnea
Obstructive sleep apnea is strongly associated with excess body weight, particularly fat around the neck and upper airway, which can narrow the airway during sleep and cause repeated breathing interruptions. Tirzepatide's approval for OSA rests substantially on its effect on body weight: by producing significant weight loss, it reduces the anatomical narrowing that drives many cases of OSA in people with obesity. This is a mechanism-adjacent effect rather than a direct action on breathing physiology, and the FDA's approval is specifically limited to adults with obesity and moderate-to-severe OSA, not sleep apnea generally.
What the SURMOUNT-OSA Trial Found
The approval was based on the SURMOUNT-OSA trial, which studied tirzepatide in two groups: people not using positive airway pressure (PAP) therapy and people already using PAP therapy. In participants not on PAP therapy, tirzepatide reduced the number of breathing disruptions per hour by an average of 25, compared with 5 in the placebo group, and 42% of tirzepatide-treated patients achieved remission or only mild residual OSA, compared with 16% on placebo. Average weight loss in this group was about 18%. In participants also using PAP therapy, tirzepatide reduced disruptions by an average of 29 per hour versus 6 for placebo, with 50% reaching remission or mild OSA versus 14% on placebo, alongside about 20% average weight loss.
What This Doesn't Mean
These results don't establish tirzepatide as a treatment for sleep apnea in people without obesity, nor do they suggest it replaces PAP therapy for everyone; the trial's PAP-plus-tirzepatide arm shows the two can be used together, and many patients with more severe OSA will still need airway pressure therapy alongside any weight-related improvement. The trial also doesn't tell us how durable the breathing improvements are if a patient later stops the medication and regains weight, a limitation shared with tirzepatide's obesity indication generally.
Safety Considerations
The safety profile for OSA treatment mirrors tirzepatide's established profile in obesity and diabetes, including gastrointestinal side effects like nausea and diarrhea as the most common adverse events, along with the drug's existing warnings regarding pancreatitis risk and thyroid C-cell tumor risk observed in animal studies, which is why tirzepatide carries a boxed warning and is contraindicated in patients with a personal or family history of certain thyroid cancers.
Talk to Your Doctor
Sleep apnea diagnosis requires a formal sleep study, and treatment decisions, including whether tirzepatide, PAP therapy, or a combination is appropriate, should be made with a physician familiar with a patient's full sleep and metabolic history rather than self-directed.
The Bottom Line
Tirzepatide's OSA approval is a genuine expansion of what a GLP-1/GIP medication can be prescribed for, grounded in a specific, well-defined trial population and mechanism. It is not a general sleep apnea cure, and its benefit in this setting is inseparable from its effect on body weight.